ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2749

Amyloidosis and Its Related Factors In Patients With Familial Mediterranean Fever: A Nationwide Multicenter Study

Timucin Kasifoglu1, Sule Yasar1, Ismail Sari2, Dilek Solmaz2, Soner Senel3, Hakan Emmungil4, Levent Kilic5, Sibel Yilmaz Oner6, Fatih Yildiz7, Sedat Yilmaz8, Muhammet Cinar9, Duygu Ersozlu Bakirli10, Muge Aydin Tufan11, Sema Yilmaz12, Veli Yazisiz13, Yavuz Pehlivan14, Cemal Bes15, Gozde Yildirim Cetin16, Sukran Erten17, Emel Gonullu1, Tuncer Temel18, Servet Akar2, Kenan Aksu4, Umut Kalyoncu5, Haner Direskeneli19, Eren Erken11, Bunyamin Kisacik20, Mehmet Sayarlioglu21 and Cengiz Korkmaz22, 1Rheumatology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, 2Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 3Rheumatology, Kayseri Erciyes University School of Medicine, Kayseri, Turkey, 4Rheumatology, Ege University School of Medicine, Izmir, Turkey, 5Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, 6Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 7Rheumatology, Cukurova University, School of Medicine, Adana, Turkey, 8Gulhane School of Medicine, Ankara, Turkey, 9Rheumatology, Gulhane School of Medicine, Ankara, Turkey, 10Rheumatology, Adana Numune Training and Research Hospital, Adana, Turkey, 11Rheumatology, Cukurova University School of Medicine, Adana, Turkey, 12Department of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, 13Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey, 14Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, 15Rheumatology, Bolu Izzet Baysal School of Medicine, Bolu, Turkey, 16Rheumatology, Kahramanmaras University School of Medicine, Kahramanmaras, Turkey, 17Rheumatology, Ataturk Training and Research Hospital, Ankara, Turkey, 18Gastroenterology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, 19Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 20Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 21Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, 22Eskisehir Osmangazi University, Eskisehir, Turkey

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: AA-amyloidosis and familial Mediterranean fever

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Autoinflammatory Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disease that occurs worldwide and predominantly affects the populations arising from the Mediterranean origin. Secondary (AA) amyloidosis still remains the most devastating complication of FMF especially in untreated and noncompliant patients. However, pathogenesis and risk factors of amyloidosis still remains only partially understood in FMF. The primary aim of this study was to investigate the prevalence of amyloidosis and its related factors in a large number of FMF patients.

Methods:

Fifteen centers from the different geographical regions of Turkey were included in the study. Detailed demographic and medical data based on structured questionnaire and medical records were collected. The diagnosis of amyloidosis was based on histological proof of congophilic fibrillar deposits in tissue biopsies. 

Results:

There were 2246 FMF patients. The male/female ratio was 0.87 (1049/1197). The mean ages of the patients were 33.6±0.25 years. Peritonitis was the most frequent clinical finding of the patients and it was present in 94.6% of the patients. The other clinical features were fever (91.9%), pleuritis (47.9%), arthritis (39.8%), erysipelas like erythema (ELE; 23.7%), myalgia (13%) and vasculitis (2.7%). Genetic testing was available in 1719 patients (76.5%). The most frequently observed genotype was homozygous M694V mutation which was present in 413 (24%) patients. Amyloidosis was present in 193 (8.6%) patients. Male sex, arthritis, M694V genotype, patients with end stage renal disease (ESRD), family history of amyloidosis and ESRD was significantly more prevalent in patients with amyloidosis compared with the amyloidosis negative subjects (Table 1). Patients with homozygous M694V mutations had significantly increased frequency of arthritis, ELE, amyloidosis, ESRD and family history of FMF and ESRD compared to the other genotypes.

Conclusion:

In this nationwide study we revealed that 8.6% of our FMF patients had amyloidosis and homozygosity for M694V was the most common mutation in these patients. The latter finding confirms the association of homozygous M694V mutation with amyloidosis in Turkish FMF patients.

Table 1:Comparison of patients with or without amyloidosis

 

Amyloidosis (+)

n=193

Amyloidosis (-)

n=2053

P

Male sex

105, (54.4)

944, (46)

0.026

Peritonitis

170, (88.1)

1956, (95.3)

<0.001

Pleuritis

73, (37.8)

1002, (48.8)

<0.001

Arthritis

99, (51.3)

796, (38.8)

0.001

Patients with ESRD

101, (52.3)

10, (0.5)

<0.001

M694V homozygosity

90, (45.6)

323, (15.7)

<0.001

Delay in the diagnosis (years)

8

7

0.147

Family history of amyloidosis

54, (28)

428, (20.8)

0.027

Family history of ESRD

32, (16.6)

81, (3.9)

<0.001


Disclosure:

T. Kasifoglu,
None;

S. Yasar,
None;

I. Sari,
None;

D. Solmaz,
None;

S. Senel,
None;

H. Emmungil,
None;

L. Kilic,
None;

S. Yilmaz Oner,
None;

F. Yildiz,
None;

S. Yilmaz,
None;

M. Cinar,
None;

D. Ersozlu Bakirli,
None;

M. Aydin Tufan,
None;

S. Yilmaz,
None;

V. Yazisiz,
None;

Y. Pehlivan,
None;

C. Bes,
None;

G. Yildirim Cetin,
None;

S. Erten,
None;

E. Gonullu,
None;

T. Temel,
None;

S. Akar,
None;

K. Aksu,
None;

U. Kalyoncu,
None;

H. Direskeneli,
None;

E. Erken,
None;

B. Kisacik,
None;

M. Sayarlioglu,
None;

C. Korkmaz,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/amyloidosis-and-its-related-factors-in-patients-with-familial-mediterranean-fever-a-nationwide-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology